Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome

M. R. Pranzatelli, E. D. Tate, J. M. Crowley, B. Toennies, Michael Creer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To evaluate the possible role of central free amino compounds in pediatric opsoclonus-myoclonus syndrome (OMS), 21 cerebrospinal fluid (CSF) amino compounds were measured by an amino acid analyzer or mass spectroscopy in 74 anesthetized children, 54 with OMS and 20 age-matched neurological controls. In OMS, only phosphoethanolamine was increased compared to controls; OMS severity and duration had significant converse effects on alanine and phosphoethanolamine. In contrast, corticotropin (ACTH) treatment was associated with increased alanine and phenylalanine, and decreased taurine compared to controls and untreated OMS, and increased glutamine, lysine, ornithine, and tyrosine compared to untreated OMS. Other than low taurine, these effects were not found with corticosteroid treatment, and non-steroidogenic immunotherapy had no effect. The ACTH dose-association was most apparent for alanine and phosphoethanolamine, but lysine and ornithine were also higher in the high-dose ACTH group. There were no significant disease- or treatment-associated perturbations in GABA, glycine, or other amino acids. These data suggest a unique pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most part not shared by steroids.

Original languageEnglish (US)
Pages (from-to)164-171
Number of pages8
JournalNeuropediatrics
Volume39
Issue number3
DOIs
StatePublished - Jun 1 2008

Fingerprint

Opsoclonus-Myoclonus Syndrome
Adrenocorticotropic Hormone
Alanine
Ornithine
Taurine
Lysine
Cerebrospinal Fluid
Amino Acids
Glutamine
Phenylalanine
Immunotherapy
Glycine
gamma-Aminobutyric Acid
Tyrosine
Mass Spectrometry
Adrenal Cortex Hormones
Therapeutics
Steroids
Pediatrics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Pranzatelli, M. R. ; Tate, E. D. ; Crowley, J. M. ; Toennies, B. ; Creer, Michael. / Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome. In: Neuropediatrics. 2008 ; Vol. 39, No. 3. pp. 164-171.
@article{3a190ce286a341168f5cc03eaff4b28d,
title = "Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome",
abstract = "To evaluate the possible role of central free amino compounds in pediatric opsoclonus-myoclonus syndrome (OMS), 21 cerebrospinal fluid (CSF) amino compounds were measured by an amino acid analyzer or mass spectroscopy in 74 anesthetized children, 54 with OMS and 20 age-matched neurological controls. In OMS, only phosphoethanolamine was increased compared to controls; OMS severity and duration had significant converse effects on alanine and phosphoethanolamine. In contrast, corticotropin (ACTH) treatment was associated with increased alanine and phenylalanine, and decreased taurine compared to controls and untreated OMS, and increased glutamine, lysine, ornithine, and tyrosine compared to untreated OMS. Other than low taurine, these effects were not found with corticosteroid treatment, and non-steroidogenic immunotherapy had no effect. The ACTH dose-association was most apparent for alanine and phosphoethanolamine, but lysine and ornithine were also higher in the high-dose ACTH group. There were no significant disease- or treatment-associated perturbations in GABA, glycine, or other amino acids. These data suggest a unique pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most part not shared by steroids.",
author = "Pranzatelli, {M. R.} and Tate, {E. D.} and Crowley, {J. M.} and B. Toennies and Michael Creer",
year = "2008",
month = "6",
day = "1",
doi = "10.1055/s-0028-1085466",
language = "English (US)",
volume = "39",
pages = "164--171",
journal = "Neuropediatrics",
issn = "0174-304X",
publisher = "Hippokrates Verlag GmbH",
number = "3",

}

Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome. / Pranzatelli, M. R.; Tate, E. D.; Crowley, J. M.; Toennies, B.; Creer, Michael.

In: Neuropediatrics, Vol. 39, No. 3, 01.06.2008, p. 164-171.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome

AU - Pranzatelli, M. R.

AU - Tate, E. D.

AU - Crowley, J. M.

AU - Toennies, B.

AU - Creer, Michael

PY - 2008/6/1

Y1 - 2008/6/1

N2 - To evaluate the possible role of central free amino compounds in pediatric opsoclonus-myoclonus syndrome (OMS), 21 cerebrospinal fluid (CSF) amino compounds were measured by an amino acid analyzer or mass spectroscopy in 74 anesthetized children, 54 with OMS and 20 age-matched neurological controls. In OMS, only phosphoethanolamine was increased compared to controls; OMS severity and duration had significant converse effects on alanine and phosphoethanolamine. In contrast, corticotropin (ACTH) treatment was associated with increased alanine and phenylalanine, and decreased taurine compared to controls and untreated OMS, and increased glutamine, lysine, ornithine, and tyrosine compared to untreated OMS. Other than low taurine, these effects were not found with corticosteroid treatment, and non-steroidogenic immunotherapy had no effect. The ACTH dose-association was most apparent for alanine and phosphoethanolamine, but lysine and ornithine were also higher in the high-dose ACTH group. There were no significant disease- or treatment-associated perturbations in GABA, glycine, or other amino acids. These data suggest a unique pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most part not shared by steroids.

AB - To evaluate the possible role of central free amino compounds in pediatric opsoclonus-myoclonus syndrome (OMS), 21 cerebrospinal fluid (CSF) amino compounds were measured by an amino acid analyzer or mass spectroscopy in 74 anesthetized children, 54 with OMS and 20 age-matched neurological controls. In OMS, only phosphoethanolamine was increased compared to controls; OMS severity and duration had significant converse effects on alanine and phosphoethanolamine. In contrast, corticotropin (ACTH) treatment was associated with increased alanine and phenylalanine, and decreased taurine compared to controls and untreated OMS, and increased glutamine, lysine, ornithine, and tyrosine compared to untreated OMS. Other than low taurine, these effects were not found with corticosteroid treatment, and non-steroidogenic immunotherapy had no effect. The ACTH dose-association was most apparent for alanine and phosphoethanolamine, but lysine and ornithine were also higher in the high-dose ACTH group. There were no significant disease- or treatment-associated perturbations in GABA, glycine, or other amino acids. These data suggest a unique pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most part not shared by steroids.

UR - http://www.scopus.com/inward/record.url?scp=57049152814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049152814&partnerID=8YFLogxK

U2 - 10.1055/s-0028-1085466

DO - 10.1055/s-0028-1085466

M3 - Article

VL - 39

SP - 164

EP - 171

JO - Neuropediatrics

JF - Neuropediatrics

SN - 0174-304X

IS - 3

ER -